Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-09

Clinical Trial Update: A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating ruxolitinib phosphate cream in plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ruxolitinib phosphate cream (ruxolitinib phosphate)

Snippet

Sponsor: Incyte Corporation | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-02-09